The authors analyze the use of mental health care resources before and after the initiation of risperidone therapy in patients of Valley Mental Health, an agency providing aggressive community-based treatment in Salt Lake County, Utah.
Sixty-three patients were treated with risperidone during the period from February 1994 through June 1995.
Data for at least 6 months before (pre-period) and after (post-period) risperidone therapy were available for 61 patients ; the mean period for which data were obtained was 31.8 months (pre-plus post-period).
Risperidone use was associated with a reduction, albeit nonsignificant, in the numbers of patients requiring acute inpatient hospital care (-29%), days hospitalized (-1 day per year), residential treatment days (-0.7 days per year), and day-treatment visits (-1.7 visits per year), together with small increases, also nonsignificant, in the need for emergency/crisis intervention (0.1 visit per year), outpatient treatment (0.1 visit per year), and case management (2.3 visits per year).
The costs of institutional plus ambulatory care declined from $7949 to $6910 per patient per year (-13%) ; the greatest reduction was in the cost of acute inpatient care (-18%). With the addition of risperidone, the cost of psychotropic medications doubled, resulting in a statistically nonsignificant mean increase in total costs of $305 per patient per year. (...)
Mots-clés Pascal : Rispéridone, Neuroleptique, Psychotrope, Schizophrénie, Chimiothérapie, Traitement, Homme, Economie santé, Coût, Etats Unis, Amérique du Nord, Amérique, Santé mentale, Soin, Ambulatoire, Hospitalisation, Traitement communautaire, Santé communautaire, Psychose
Mots-clés Pascal anglais : Risperidone, Neuroleptic, Psychotropic, Schizophrenia, Chemotherapy, Treatment, Human, Health economy, Costs, United States, North America, America, Mental health, Care, Ambulatory, Hospitalization, Community treatment, Community health, Psychosis
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 98-0297607
Code Inist : 002B02B03. Création : 27/11/1998.